R&D channel feed – Endpoints News

R&D channel feed

Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial

6 years ago

Ex-GSK chief Andrew Witty summoned back to the frontlines of vaccine development at embattled WHO

6 years ago

Gilead takes a hit after a closely-watched Covid-19 trial of remdesivir is quietly terminated, raising fresh doubts

6 years ago

As GSK and Sanofi promise to produce a Covid-19 vaccine at Indy 500 speed, some experts start to push back on timelines

6 years ago

Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway

6 years ago

Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data

6 years ago

Moderna's mission to spearhead a revolution in vaccine R&D comes center stage today as the world faces a crucial turning point

6 years ago

Creative or unethical? Researchers’ Covid-19 GoFundMe campaign spurs critics

6 years ago

Q&A: Analyst-turned biotech exec-turned analyst reads the biotech Q1 tea leaves

6 years ago

AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy

6 years ago

Judge slaps enhanced damages on Gilead/Kite for ‘willful’ patent violation, boosting award to a blockbuster $1.2B — with the meter running

6 years ago

A small remdesivir study with lots of shortcomings suggests it may be working against Covid-19 — and 1 analyst forecasts mid-May rollout

6 years ago

Natural killers are coming for Covid-19 and the therapy, experts say, could make things worse

6 years ago

Tango Therapeutics nabs $60M in CRISPR-based hunt for hidden cancer genes

6 years ago

Did Gilead just lower the bar on crucial remdesivir trials for Covid-19? Switching endpoints, amping up trial size stir analysts' fears — and hopes

6 years ago

Zai Lab finds latest target in Regeneron’s bispecific, paying up to $190M for Chinese rights

6 years ago

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

6 years ago

Blasted by PhIII failure, a struggling Sage axes 340 staffers and bunkers down to survive the storm

6 years ago

Pivotal failure crumbles stock for Michigan’s once-promising Millendo

6 years ago

Ready to declare a definitive comeback in two months, Immunomedics stops PhIII early, recruits new CEO

6 years ago

Small molecules, biologics and now gene therapies: Germany's Evotec adds another feather to its R&D cap

6 years ago

A pair of PhIII failures spells last rites for Menlo’s once-promising Merck drug

6 years ago

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

6 years ago

GSK's Hal Barron buys a $250M stake in George Scangos' Vir and makes a beeline to the clinic with Covid-19 antibodies

6 years ago

First page Previous page 205 206 207208209 210 211 Next page Last page